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The ubiquitin-modification status of proteins in cells
is highly dynamic and maintained by specific ligation
machineries (E3 ligases) that tag proteins with
ubiquitin or by deubiquitinating enzymes (DUBs)
that remove the ubiquitin tag. The development of
tools that offset this balance is critical in character-
izing signaling pathways that utilize such ubiquitina-
tion switches. Herein, we generated a DUB-resistant
ubiquitin mutant that is recalcitrant to cleavage by
various families of DUBs both in vitro and in mam-
malian cells. As a proof-of-principle experiment,
ectopic expression of the uncleavable ubiquitin
stabilized monoubiquitinated PCNA in the absence
of DNA damage and also revealed a defect in the
clearance of the DNA damage response at unpro-
tected telomeres. Importantly, a proteomic survey
using the uncleavable ubiquitin identified ubiquiti-
nated substrates, validating the DUB-resistant ubiq-
uitin expression system as a valuable tool for
interrogating cell signaling pathways.INTRODUCTION
The ubiquitination status of a target protein is achieved via a
delicate balance between two opposing forces: ubiquitin E3
ligases andDUBs. It has been postulated that themajority of pro-
teins in a cell are regulated and modified by ubiquitin at some
point (Hershko and Ciechanover, 1998); however, it has proved
difficult to demonstrate the ubiquitination status of these pro-
teins, as many of the modifications only exist transiently in vivo,
owing largely to the multitude of DUBs present in cells. There
are nearly 100 DUBs encoded in the human genome, which
comprise approximately one-fifth of all proteases (Rawlings
et al., 2010). DUBs are divided into five subfamilies based on
catalytic mechanism and the fold of the active site domain
(Reyes-Turcu et al., 2009). The largest family are the ubiquitin-826 Cell Reports 5, 826–838, November 14, 2013 ª2013 The Authorsspecific proteases (USPs), followed by the ovarian tumor DUBs
(OTUs), the ubiquitin C-terminal hydrolases (UCHs), the Josephin
DUBs, and, last, the JAMM/MPN+ family member DUBs. Except
for the JAMM/MPN+ family of DUBs, which are zinc-dependent
metalloproteases, all other characterized DUBs are cysteine
proteases. As the ubiquitin-modified status of a protein can
fundamentally alter its properties and change its biological role,
it is critical to capture the ubiquitinated state of a protein in order
to investigate its biological function both in vitro and in vivo.
The ubiquitin system has recently been exploited with the
design of unique ubiquitin mutants that inhibit specific DUBs
(Ernst et al., 2013; Zhang et al., 2013). Although the specificity
of such mutants is remarkable, generating a novel mutant for
each DUB has to begin de novo and is quite laborious, especially
when the physiological substrates of many DUBs remain
unknown. In this study, we designed and generated a DUB-
resistant ubiquitin to capture and identify transiently ubiquiti-
nated DUB substrates. Building on previous work in the SUMO
conjugation and deconjugation pathway (Be´ke´s et al., 2011),
we have generated a ubiquitin mutant (UbL73P) that is pleiotro-
pically resistant to cleavage by multiple DUB families. This
uncleavable ubiquitin mutant is conjugated to protein substrates
in mammalian cells and leads to ubiquitin-conjugate stabiliza-
tion. Ectopic expression of the DUB-resistant ubiquitin mutant
stabilized monoubiquitinated PCNA, leading to the aberrant
recruitment of translesion synthesis (TLS) polymerases in the
absence of DNA damage, mimicking the effect of USP1 loss.
Additional studies with DUB-resistant ubiquitin revealed a
ubiquitin switch in the clearance of the DNA damage response
(DDR) at shelterin-deficient chromosomal ends and captured
ubiquitin-stabilized substrates by mass spectrometry. Our
work provides a framework to study deubiquitination-dependent
events both in vitro and in mammalian cells through the genera-
tion and use of the DUB-resistant ubiquitin tool.
RESULTS
Ubiquitin-L73P Is a DUB-Resistant Ubiquitin Mutant
To establish a ubiquitin mutant that would be resistant to cleav-
age by DUBs, wemutated Leu73 of ubiquitin to Pro. Leu73 is the
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P4 position of the DUB cleavage site in the C terminus of ubiqui-
tin (Figure 1A); the analogous mutation in SUMO2 (Figure S1A)
results in a conjugatable but deconjugation-resistant SUMO
(Be´ke´s et al., 2011). To test the ‘‘uncleavability’’ of UbL73P in
the context of a linear peptide bond, we expressed recombinant
linear diubiquitin (M1 linked) containing the L73P mutation in
both ubiquitin moieties with an N-terminal Smt3-tag (Figure 1B)
and tested it as a substrate for USP2CD (Figures 1C and S1B).
Although thewild-type (WT) fusion protein is cleaved byUSP2CD,
the mutant (L73P) is not. To ensure that the Smt3-tag did not
interfere with cleavage of the L73P di-Ub, the tag was removed
via cleavage with Ulp1 and the di-Ub was purified to homo-
geneity and subjected again to USP2CD cleavage (Figure 1D).
These results show that, in the context of a linear peptide
bond, L73P is refractory to cleavage.
To test whether UbL73P in the context of an isopeptide bond is
also resistant to cleavage, we generated K63-linked ubiquitin
chains using Ubc13 (UBE2N-Uev1a) in an in vitro ubiquitination
reaction (Figure S1C, lanes 1–2 and 5–6). Whereas wild-type
diubiquitin prepared using Ubc13 is cleaved by USP2CD (Fig-
ure 1E, lanes 1–4), di-UbL73P is completely resistant to cleavage
(Figure 1E, lanes 5–8). Additionally, higher molecular weight,
unanchored polyubiquitin chains, also prepared using Ubc13,
are likewise resistant to cleavage in the context of UbL73P (Fig-
ure S1C, lanes 3–4 and 7–8). Interestingly, themore conservative
L73A mutation on ubiquitin is only partially resistant to cleavage
by USP2CD (Figure 1E, lanes 9–12). This suggests that it is the
combination of the altered topology of the proline residue; the
loss of the hydrophobic interaction provided by the leucine
side chain; and the loss of its hydrogen-bonding ability to
Asp295 of USP2 (Renatus et al., 2006) that renders UbL73P
‘‘uncleavable’’ (Figure S1D). Consistent with the latter being
most significant, mutation of USP7 Asp295 to Ala results in an
inactive enzyme (Hu et al., 2002). We show that purified
linkage-specific ubiquitin chains produced in vitro are also resis-
tant to cleavage bymultiple USP familymembers (Figures 1F and
1G), by theK63-specific JAMM familymember AMSH (Figure 1H)
and by the K48-specific OTU-domain family member Otubain-1
(Figure 1I). Finally, we show that K11 linkages are also resistant
to cleavage (Figure 1J). Collectively, these in vitro studies estab-
lish UbL73P as a pan-DUB resistant ubiquitin mutant, encom-
passing both cysteine protease and metalloenzyme DUBs.Figure 1. UbL73P Is a Pan-DUB DUB-Resistant Ubiquitin Mutant In Vit
(A) Surface representation of ubiquitin (PDB: 1UBQ) detailing its C terminus. The D
Leu73 shown in green. The Ile44 hydrophobic patch is colored brown on the su
generated using PyMol.
(B) Schematic representation of Smt3-tagged linear diubiquitin. Ubiquitin L73P is
(C and D) Wild-type and L73P Smt3-linear-di-Ub, before (C) and after (D) Ulp1-c
(E) Untagged monoubiquitins were used to make K63-linked diubiquitins using U
(F) Recombinant USP1/UAF1 complex was used to cleave wild-type and L73P (N
(G) Linkage-specific tetra-ubiquitin chains (K48-linked, left panel, or K63-linked, ri
chains) were cleaved with an assortment of USP-family DUBs.
(H) DUBs representing the USP family (USP2CD), the OTU-domain family (Otubain
K63-linked tetraubiquitin chains. Otubain-1 serves as a negative control for K63.
(I) Otubain-1 and USP2CD were used to cleave K48-linked diubiquitin.
(J) USP2CDwas used to cleave K11-linked diubiquitin. Dotted lines indicate croppi
SDS-PAGE and Coomassie staining.
See also Figure S1.
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Both In Vitro and In Vivo
We have previously shown that UbL73P supports unanchored
ubiquitin chain formation by Ubc13 as the E2 enzyme (Figures
1E and S1C). However, owing to the unique topology of
UbL73P, we postulated that not all ubiquitin conjugation path-
ways will utilize it equally. Thus, we asked whether the two
human E1 enzymes, Ube1 and Uba6, which have been shown
to dictate downstream ubiquitination events in vivo (Jin et al.,
2007), showed preference between wild-type and UbL73P. In
an in vitro E1 charging reaction, Ube1 and Uba6 differ only
slightly in UbL73P charging (Figure 2A); however, Uba6 cannot
use UbL73P in charging UbcH7 in an E2-charging reaction (Fig-
ure 2B). Importantly, when UbL73P is utilized by Ube1 to charge
an E2 enzyme, it depends on the active site cysteine of the E2,
indicating that the charging is enzyme catalyzed (Figure S2A).
Together, these results suggest that UbL73P usage in vivo is
dictated at the E1 level; differences in E1 thioester formation
between Ube1 and Uba6 could be due to the different residues
that contact Leu73 in Ube1 and Uba6 (Figures S2B and S2C)
during E1 charging (Olsen and Lima, 2013). On the other hand,
there is no crystal structure available for a charged E2 enzyme
still bound to an E1; therefore, the differential E2 charging ability
of Uba6 in the context of UbL73P is difficult to explain mechanis-
tically at this stage.
Because Leu73 is part of the Ile36 hydrophobic patch of
ubiquitin that is important in ubiquitin chain assembly (Komander
and Rape, 2012), we asked whether the L73P mutation affects
conjugation to substrates using E3 ligases. The recently solved
crystal structures of RING-E2:E3 complexes highlight an
intermediate role of Leu73 in E2-E3 interactions (Dou et al.,
2012; Plechanovova´ et al., 2012). Consistent with the structural
analysis, UbL73P is conjugated to the model substrate p53 by
both RING- and HECT-domain E3 ligases with reduced
efficiency (Mdm2, Figure 2C, and E6AP, Figure 2D, respectively).
Importantly, however, UbL73P-conjugated p53-Ubn remains
uncleavable by USP2CD (Figure 2E).
We next sought to determine whether UbL73P, when
expressed in mammalian cells, is incorporated into ubiquitin
conjugates. We generated N-terminal HA-tagged wild-type
and L73P ubiquitin constructs ending in Gly76 to allow for imme-
diate conjugation. When expressed in U2OS cells, UbL73Pro
UB cleavage site (P4-P1, aa 72–76 of ubiquitin) is shown in sticks (in black), with
rface, whereas the Ile36 hydrophobic patch is colored pink. The image was
not cleaved by DUBs neither as a peptide or an iso-peptide bond.
leavage and final purification, was cleaved with a serial dilution of USP2CD.
bc13/Uev1a and then subjected to cleavage by USP2CD.
H) tetraubiquitin chains in vitro.
ght panel) made using either wild-type or L73P ubiquitin (nonhydrolyzable [NH]
-1) and the JAMM-metallo-DUBs (AMSH) were used cleave wild-type and NH
ngwithin the same gel. Assayswere carried out at 37C for 1 hr and analyzed by
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Figure 2. UbL73P Is Conjugated to Substrates In Vitro and In Vivo
(A) E1 charging assay with GST-tagged human Ube1 and Uba6 using wild-type and L73P ubiquitin.
(B) E2 charging assay using human GST-tagged Ube1 and Uba6 as the E1 and human UbcH7 as the E2, using wild-type and L73P ubiquitin (F). E1 and E2
charging reactions were carried out at 37C in the absence of DTT and analyzed by nonreducing SDS-PAGE and SYPRO staining.
(C and D) p53-ubiquitination reactions with wild-type and L73P ubiquitin using either a RING-finger E3 ligase, Mdm2 (C), or a HECT-domain E3 ligase, E6AP (D).
Ubiquitination reactions with the E3 ligases were analyzed by denaturing SDS-PAGE and western blotting with a p53 antibody. Dotted lines indicate cropped
images from the same gel.
(E) Mdm2-generated ubiquitin chains on p53 using WT or L73P ubiquitin were cleaved with USP2CD following ubiquitination reactions.
(F) Expression of HA-tagged wild-type and L73P ubiquitin in U2OS cells results in stabilization of Ub-conjugates by L73P, such as PCNA-Ub.
See also Figure S2.
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forms Ub conjugates similar to wild-type Ub, with a modest
increase in higher -molecular weight (HMW) Ub conjugates (Fig-
ure 2F, left panel), likely forming heterogenous chains with
endogenous ubiquitin. Under these conditions, levels of ectopi-
cally expressed ubiquitin do not reach endogenous levels, as
judged by total Ub (Figures S3A and S3B).
Intriguingly, expression of UbL73P resulted in a marked
increase in the monoubiquitination of PCNA (Figure 2F, right
panel), a substrate previously shown to be monoubiquitinated
under DNA damage conditions (Hoege et al., 2002). Nonspecific
ubiquitination was not observed for other proteins, such as
MCM6 (Figure 2F, bottom). Importantly, we show that PCNA
modification with cleavage-resistant modifiers is specific to
ubiquitin, as cleavage-resistant SUMO2 does not stabilize
PCNA conjugates under normal conditions (Figure S3C). The
monoubiquitination of PCNA is usually reversed by USP1 (Huang
et al., 2006); however, USP1 does not cleave UbL73P chains
(Figure 1F). These results strongly suggest that the UbL73P-
stabilized PCNA monoubiquitination is a result of the failure of
USP1 to cleave UbL73P from PCNA in cells.
UbL73P Expression Inhibits the Deubiquitination
of PCNA in the Absence of DNA Damage
We next focused on how stabilized UbL73P conjugates lead to
higher levels of PCNA monoubiquitination (Figure 2F). UbL73P
conjugates produced from cells remain refractory to an in vitro
DUB (USP2) cleavage assay (Figure 3A, lanes 1–8). Interestingly,
whereas expression of both UbL73A and UbG76A give rise to
similar patterns of HMW ubiquitin conjugates in cells, they
remain relatively sensitive to cleavage by USP2CD in vitro (Fig-
ure 3A, lanes 9–16). An earlier study showed that UbG76A can
accumulate as K48-linked unanchored ubiquitin oligomers in
cells (Hodgins et al., 1992). Collectively, this suggests that
UbG76A is not universally refractory to cleavage by DUBs, but
it is resistant only to USP5 (IsoT)-mediated deubiquitination
(Dayal et al., 2009), which requires an intact C-terminal GlyGly
motif for unanchored chain deconjugation (Wilkinson et al.,
1995).
In agreement with the DUB cleavage sensitivity of different
ubiquitin mutants in vitro (Figures 1E and 3A), expression of
neither UbL73A nor UbG76A stabilize PCNA monoubiquitination
in cells (Figure 3B). Importantly, we show that PCNA mono-
ubiquitination by UbL73P is restricted to the canonical ubiquiti-
nation lysine of PCNA, because coexpression of a K164RFigure 3. Dynamic PCNA Monoubiquitination Revealed by UbL73P
(A) HA-Ub constructs were expressed in HEK293 cells, lysed under nondenaturi
(B) HA-Ub constructs were expressed in U2OS cells and lysed under denaturing
(C) PCNAwith a K164Rmutation does not support monoubiquitination by UbL73P
lysed under denaturing conditions.
(D) UbL73P is conjugated in a Rad18-dependent manner in vivo. U2OS cells were
48 hr when cell lysates were prepared under denaturing conditions.
(E) UbL73P-stabilized PCNA-Ub recruits polymerase eta in the absence of DNA d
cells, fixed in methanol, mounted with DAPI, and analyzed by immunofluorescenc
representative images and western blots for the cell lysates analyzed. Error bars
(F) Dynamic PCNA monoubiquitination revealed by UbL73P. Under normal circum
which is counterbalanced by USP1, the DUB for PCNA. When a conjugatable, b
USP1-arm of the dynamic PCNA monoubiquitation cycle is poisoned, leading to
See also Figure S3.
CePCNA mutant does not support monoubiquitination with
UbL73P (Figure 3C). We also show that UbL73P-stabilized
PCNA monoubiquitination is dependent on the endogenous E3
ligase for PCNA, Rad18 (Kannouche et al., 2004), because small
interfering RNA (siRNA) knockdown of Rad18 reduces PCNA
monoubiquitination levels (Figure 3D). These results strongly
suggest that UbL73P conjugation is specific to a physiological
substrate and its lysine residue, and it occurs via its endogenous
E3 ligase. Finally, we show that UbL73P-stabilized PCNA mono-
ubiquitination aberrantly recruits TLS polymerase ETA to the
replication fork, represented by nuclear foci (Figure 3E). This is
in accordance with earlier work showing that knockdown of
USP1, which leads to the accumulation of monoubiquitinated
PCNA even in the absence of DNA damage, is sufficient to recruit
TLS polymerases to the replication fork and forms nuclear foci
(Jones et al., 2012). These results demonstrate that UbL73P is
utilized similarly as wild-type ubiquitin and is conjugated onto
protein substrates in UbL73P-expressing cells. This ‘‘proof-of-
principle’’ highlights the use of UbL73P as a tool to reveal
ubiquitin switches (as demonstrated by the balance between
ubiquitin conjugation and deconjugation cycles), such as for
PCNA in unperturbed cells (Figure 3F).
UbL73P Expression Attenuates the Clearance of 53BP1
Foci after Telomeric DDR in Shelterin-Deficient MEFs
We next sought to determine whether UbL73P can be used to
interrogate DNA repair pathways that are regulated by ubiquitin
switches. Distinct E3 ligases and DUBs are critical regulators of
the double-strand break repair and response in mammalian cells
(Jackson and Durocher, 2013). Signaling and repair emanating
from DNA damage recognition is carried out, in part, through
mono- and polyubiquitin interactions with different ubiquitin-
binding domains (UBDs) on specific DNA damage response
(DDR) proteins. To determine if UbL73P can be utilized and
recognized by DDR proteins, we first addressed whether
UbL73P conjugates are recognized by UBDs other than those
of the TLS polymerases. Indeed, UBD pull-down experiments
using theUIMs (ubiquitin-interactingmotifs) of RAP80 (Figure 4A)
and S5a (Figure S4A) indicate that polyubiquitin conjugates from
cell extracts that have incorporated UbL73P are efficiently
captured by different UBDs. To address whether K63 linkage-
specific polyubiquitin chains can be recognized and captured
by the RAP80 UBD in the context of the UbL73P-stabilized
chains, UbL73P containing only a single lysine site at K63 wasng conditions, and the lysates were treated with a serial dilution of USP2CD.
conditions.
. HA-PCNA andmyc-ubiquitin constructs were coexpressed in U2OS cells and
treated with siRNAs for 24 hr and then transfected with HA-ubiquitin for another
amage. HA-tagged Ubs were coexpressed with GFP-tagged Pol eta in U2OS
e microscopy using GFP antibodies for nuclear GFP-ETA foci. The inlets show
represent SD of the mean, n = 3.
stance in S-phase (top panel) the E3 ligase Rad18 monoubiquitinates PCNA,
ut not deconjugatable ubiquitin (L73P, bottom panel) is expressed in cells, the
the stabilization of PCNA-Ub.
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expressed in cells and was shown to form polyubiquitin chains
that could be selectively enriched by the RAP80 UBD in a pull-
down experiment (Figure 4B).
A critical DDR regulator is the RAP80 DUB complex, contain-
ing the K63 linkage-specific metalloprotease BRCC3 (Kim
et al., 2007; Sobhian et al., 2007; Wang et al., 2007). Based
on the observation that RAP80 UIMs bind UbL73P-stabilized
K63-Ub conjugates and the recent report supporting the
requirement of BRCC3 to prevent the accumulation of 53BP1
foci at telomeres in the absence of the shelterin component
TRF2 (Okamoto et al., 2013), we sought to determine whether
expression of UbL73P contributes to the dynamics of 53BP1
foci accumulation. In mouse embryonic fibroblasts (MEFs)
lacking TRF2, spontaneous activation of DDR occurs, leading
to gH2AX (Ser139 phosphorylation) and 53BP1 foci accumula-
tion at the chromosome ends. These DNA damage foci are
cleared following the nonhomologous end-joining (NHEJ)-
mediated ‘‘repair’’ of dysfunctional telomeres that results in
end-to-end chromosome fusions (Celli and de Lange, 2005).
To determine whether expression of UbL73P prevents dissipa-
tion of the DNA damage signal in this experimental setting, we
compared lentiviral transduction of UbWT or UbL73P in
4-hydroytamoxifen-treated Trf2Floxed/Floxed MEFs carrying an
inducible Cre recombinase (Rosa26-CreERT2) to activate
DDR (Okamoto et al., 2013). Following Cre activation, we moni-
tored 53BP1 localization at telomeres immediately after TRF2
depletion (day 3) and at a later time point when the
vast majority of telomeres have been processed by the
NHEJ-mediated repair (day 7). Intriguingly, whereas the initial
accumulation of 53BP1 foci is not affected by UbL73P, the
clearance of 53BP1 foci is significantly attenuated at day 7
(Figures 4C and 4D, right panels), suggesting that deubiquitina-
tion (likely through BRCC3) is required for 53BP1 clearance.
Importantly, UbL73P expression does not globally activate
DDR on its own (as observed by the absence of spontaneous
gH2AX levels) nor does it affect the rate of NHEJ at telomeres,
as judged by occurrence of telomere fusions (Figure 4E). On
the contrary, expression of UbL73P does not affect the clear-
ance of DNA damage foci at DSBs occurring randomly in the
genome, as shown by the dissipation of 53BP1 foci in cells
treated with ionizing radiation (IR) or bleomycin (Figures S4B–
S4D). These results suggest that although clearance of DDR
factors at TRF2-depleted telomeres depends strictly on a
UbL73P-stabilized protein substrate(s), additional pathways
may act at DSBs that occurred randomly in the genome. Simi-
larly, activation of the DDR at TRF2-depleted telomeres is
strictly dependent on the ATM DDR kinase, whereas irradiationFigure 4. Ubiquitin-Conjugate Stabilization Reveals a Telomeric DNA D
RAP80-mediated pull-down of UbL73P conjugates.
(A and B) HA-ubiquitin constructs were expressed in HEK293 cells and lysed
RAP80-conjugated beads and then analyzed by SDS-PAGE and western blottin
(C) TRF2F/F; Rosa26 CRE-ER MEFs infected with the indicated constructs were t
DNA (green), and DAPI (blue).
(D) Quantification of cells with less than ten 53BP1 foci (<10) or more than 30 53B
(E) Metaphase spreads were harvested from TRF2F/F; Rosa26 CRE-ER MEFs
HA-UbL73P and stained for telomere DNA (green) and DAPI (red). Percentages of
the percentage of chromosome fusions in MEFs infected with the indicated cons
See also Figure S4.
Ceinduced foci (IRIFs) are largely unaffected in ATM-deficient
cells (Denchi and de Lange, 2007).
Identification of Ubiquitin-Stabilized Substrates in HeLa
Cells Using an UbL73P Expression System
We sought to establish the utility of UbL73P in identifying
ubiquitin-stabilized substrates by creating a stable cell line
expressing UbL73P, purifying Ub conjugates and identifying
the substrates and ubiquitination sites by mass spectrometry.
We generated a doxycyclin-inducible HeLa cell line stably
expressing low levels of FLAG-Ub-WT (Flp-in-WT) and FLAG-
Ub-L73P (Flp-in-L73P) (Figure 5A). Purifying FLAG conjugates
from Flp-in cells confirmed PCNA-Ub stabilization using
UbL73P (Figure 5B), whereas the low levels of FLAG-Ub-L73P
expressed did not affect the NFkB signaling pathway, because
ubiquitin-mediated proteasomal degradation of IkBa following
TNF-a treatment was comparable in both Flp-in-WT and Flp-
in-L73P cells (Figure S4E). Next, we scaled up and purified
FLAG-Ub conjugates from Flp-in-L73P cells and subjected
them to mass spectrometry-based protein identification. We
identified potential ubiquitinated substrates, including previously
validated ones (Table S1). Importantly, wewere also able to iden-
tify ubiquitination sites for a handful of proteins (Figure 5C),
including Lys164 of PCNA (Figure 5D), validating our approach.
Interestingly, we identified Ubc13 as a ubiquitinated substrate
at Lys92 (Figure 5E). The ubiquitination stabilization of Ubc13
by UbL73P, and not by WT ubiquitin, was confirmed in U2OS
cells for endogenous Ubc13 (Figure 5F) as well as by
coexpression of FLAG-Ubc13 and HA-ubiquitins (Figure 5G).
These results unequivocally demonstrate the utility of UbL73P
in stabilizing and identifying ephemeral ubiquitin conjugates
that would otherwise constantly undergo deubiquitination
by DUBs.
DISCUSSION
In summary, we have introduced and characterized a ubiquitin
point mutant capable of conjugating to cognate substrates and
incorporating into ubiquitin chains, yet remains refractory to
cleavage by DUBs. This provides a unique tool to enable the
generation, identification, and study of substrates with stabilized
ubiquitination states. Previous work by Be´ke´s et al. (2011) on the
related ubiquitin-like molecule SUMO2 showed that mutation in
the P4 position of the SUMO cleavage site for deSUMOylating
enzymes (SENPs) from glutamine to proline (Figure S1A, Q90P,
which is also found naturally in the pseudogene, SUMO4 [Bohren
et al., 2007]), results in resistance to cleavage by deSUMOylatingamage Response Phenotype
under nondenaturing conditions, and Ub conjugates were pulled down with
g for the indicated antibodies.
reated with 4-hydroxytamoxifen (+OHT) and stained for 53BP1 (red), telomere
P1 foci (>30) per nucleus at the indicated time points following OHT treatment.
7 days following OHT treatment. Cells were infected with either HA-Ub or
chromosomeswith fusions are indicated. Bar graph in the lower panel indicates
tructs and either treated with tamoxifen (+OHT) or untreated (OHT).
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enzymes, allowing the generation of stabilized SUMO2-
conjugates in cells. We then asked whether mutation of the
corresponding residue (Leu73) on ubiquitin could affect ubiquitin
cleavage reactions by DUBs, and we indeed show that it does.
Interestingly, in an alanine-scanning mutagenesis study of yeast
ubiquitin more than a decade ago, it was shown that UbL73A
allows for ubiquitin conjugation; however, the mutant is partially
defective in an S. cerevisiae endocytosis assay (Sloper-Mould
et al., 2001). A recent study has also identified bulky Leu73
mutations that differentially affect conjugation and deconjuga-
tion activities (Zhao et al., 2012). Furthermore, yeast provided
with the UbL73A mutant as the only source of ubiquitin cannot
support vegetative growth (Sloper-Mould et al., 2001). It is
possible that the Leu73 mutant phenotype of ubiquitin in yeast
is a composite of defects in conjugation as well as deconjuga-
tion. Leu73 contributes to part of the hydrophobic patch in
ubiquitin centered around Ile36, which is utilized by some E3
ligases to synthesize polyubiquitin chains (Plechanovova´ et al.,
2012). Therefore, in accordance with our in vitro E1/E2/E3 conju-
gation data, it is possible that certain substrates, whose E3
ligases solely rely on ubiquitin Ile36 hydrophobic interactions,
would not be efficiently conjugated by UbL73P. This selectivity
at the E3 level, together with the selectivity of the E1 enzymes,
Ube1 and Uba6, in differentially charging E2 enzymes, suggests
that the conjugation of UbL73P in vivo would be skewed toward
conjugation pathways that can tolerate it. Nevertheless, those
UbL73P conjugates would remain stable and resistant to DUBs
in cells, as is the case formonoubiquitinated PCNA, the identified
Ubc13, unknown factor(s) in the telomeric DDR pathway, and
others.
Increased levels of PCNA monoubiquitination by UbL73P
expression in a damage-independent manner mimics the
phenotype observed for USP1 knockdown (Huang et al.,
2006; Jones et al., 2012). USP1 is the only DUB to date shown
to remove ubiquitin from PCNA in vivo. This finding reveals the
highly dynamic nature of PCNA monoubiquitination in undam-
aged cells by the Rad18-USP1 E3-DUB cycle and underscores
the crucial regulatory role of USP1 in maintaining PCNA in an
unubiquitinated state. This regulation ensures that PCNA mono-
ubiquitination will not serve as a platform to recruit low-fidelity
translesion synthesis (TLS) polymerases (Lehmann et al.,
2007) in the absence of DNA damage. Failure to maintain
appropriate PCNA monoubiquitination levels could result in
increased TLS polymerase recruitment, such as that of poly-Figure 5. UbL73P Reveals Stabilized Ubiquitination of Ubc13 and Othe
(A) Schematics for the generation of HeLa Flp-in cells stably expressing ubiquitin
(B) Anti-FLAG immune precipitation of Flp-in cells treated for the indicated tim
antibody.
(C) Selected list of proteins conjugated by UbL73P and the peptides containing
(D) MS/MS spectrum of the doubly charged ion of the peptide (DLSHIGDAVVIS
modification on the first lysine residue) for Lys164 of PCNA.
(E) MS/MS spectrum of the triply charged ion of the peptide (ICLDILKGGDK carbo
first lysine residue) for Lys92 of Ubc13. Observed peptide bond cleavages are ind
and C-terminal (y-type ions) ion series for the observed fragment ions are shown
b-type ions are not indicated in the spectra.
(F) HA-Ub constructs were expressed in U2OS cells, lysed under nondenaturing
(G) FLAG-Ubc13 and HA-Ub constructs were coexpressed in U2OS cells, lysed
See also Figure S4 and Table S1.
Cemerase kappa (Jones et al., 2012), which increases genomic
instability.
Despite the important role of ubiquitination-dependent mech-
anisms in DSB repair (Jackson and Durocher, 2013), UbL73P
displayed no global defects in DNA repair mechanisms following
bleomycin treatment or ionizing radiation, perhaps because
UbL73P was incompletely utilized or because the need for
deubiquitination was bypassed. However, the phenotype
brought about by UbL73P, in the context of the activation of
spontaneous DNA damage response in the absence of the
shelterin complex at telomeres, suggests that UbL73P is a func-
tional player and results in the Ub conjugate stabilization of one
or more factors that are required for efficient 53BP1 clearance at
chromosomal ends. This is in accordance with a recent finding
showing that telomeric and genomic DDR pathways are quite
different (Cesare et al., 2013): telomeric DDR does not activate
checkpoint signaling and could rely on entirely different sets of
effector proteins, some of which could be sensitive to stabilized
ubiquitination. The telomeric UbL73P phenotype mimics the one
observed with the knockdown of BRCC3, which opposes the
activity of RNF168 at telomeres (Okamoto et al., 2013). The iden-
tity of the ubiquitinated substrate(s) that are responsible for the
activation/regulation of telomeric DDR is currently unknown. In
the future, it will be important to discern global versus telomeric
ubiquitination substrates in DNA damage response pathways.
In our exploratory UbL73P substrate identification survey, we
validated the approach by identifying known ubiquitination sites
on PCNA and others (Povlsen et al., 2012; Zhou et al., 2008). We
also identified several ubiquitinated substrates stabilized by
UbL73P. We were able to confirm the ubiquitination of Ubc13
on Lys92, a previously indicated site of ISG15 modification
(Giannakopoulos et al., 2005). Additionally, we identified the
site of ubiquitination on Ube2T, another E2 enzyme that has
been previously shown to be ubiquitinated (Machida et al.,
2006). Intriguingly, several other E2 Ub-conjugating enzymes
were found in our mass spectrometry results. Whether reversible
E2 ubiquitination is a regulatory posttranslational modification
common to a variety of E2 enzymes remains to be determined.
The utility of DUB-resistant ubiquitin tools is highly promising.
First, it is possible to ubiquitinate substrates using UbL73P
in vitro and assay the stable Ub conjugate in subsequent binding
or affinity purification experiments in search of binding partners.
Second, the UbL73P-stabilized ubiquitin chains of a defined link-
age could also be utilized to identify substrates modified by ar Targets
constructs.
es with doxycycline to induce transgene expression, probed with anti-PCNA
the Ub-modified Lys residues.
CAKGGDGVK carboxymethylated on the Cys (*) residue and carrying a GlyGly
xymethylated on the Cys (*) residue and carrying a GlyGly modification on the
icated in the sequences. The corresponding theoretical N-terminal (b-type ion)
above and below the sequence, respectively. Neutral loss of water from y- and
conditions, and probed with the indicated antibodies.
under denaturing conditions, and probed with FLAG antibody.
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particular ubiquitin chain linkage or identify binding proteins
unique to a particular ubiquitin chain linkage. This approach
will be most beneficial for chains utilizing hitherto uncharacter-
ized linkages, such as Lys29 and Lys33, and will also allow the
purification and identification of ubiquitin receptors that recog-
nize these unique chains. Finally, as unanchored oligomeric
ubiquitin chains appear to be stabilized by both UbG76A and
by UbL73P, such DUB-resistant ubiquitin mutants have the
potential to shed light on the nature and the dynamics of de
novo unanchored ubiquitin chain formation, both in resting cells
and in a signal inducible manner. This has been a relatively unex-
plored area of research, as only recently have unanchored ubiq-
uitin chains been implicated in kinase activation (Xia et al., 2009)
and in antiviral immunity (Zeng et al., 2010). As long as the conju-
gation competency for a particular pathway is adequate,
we envision the use of DUB-resistant ubiquitins and other
isopeptidase-resistant ubiquitin-like molecules by researchers
who seek to interrogate ubiquitin and ubiquitin-like-mediated
biological processes in a wide range of experimental settings.
EXPERIMENTAL PROCEDURES
In Vitro Ubiquitination and Deubiquitination Reactions
Unless otherwise indicated, ubiquitination and E1- and E2-charging reactions
were carried out as previously described (Petroski and Deshaies, 2005).
Briefly, in 30 mM HEPES (pH 7.5), 100 mM NaCl, 5 mM MgCl2, and 20 mM
ubiquitin (WT or its mutants) were incubated with E1 and E2 enzymes at 150
and 500 nM, respectively, in the presence or absence of 2 mM ATP for the
indicated times at 37C and boiled immediately in sample buffer (±5 mM
DTT for nonreducing/reducing gels) to terminate the reaction. For the
deubiquitination assay of Ubc13(Ubc13/Uev1a heterodimer)-conjugated diu-
biquitin, the ubiquitin assay described above was performed for 1 hr, and
then the reaction was terminated with 25 mM EDTA for 10 min and diluted
(4/5) into a serial dilution of USP2CD, and the mix was incubated for another
hour at 37C. For the single time point in vitro DUB assays, 2 mg wild-type of
L73P (nonhydrolyzable, NH) ubiquitin tetramers were cleaved with 100 nM
DUBs for 1 hr at 37C and analyzed by SDS-PAGE and Coomassie staining.
For USP2CD serial dilutions (with 1 mg of linear chains or with Ubc13-produced
K63-chains or with 10 mg total cell lysates), USP2CD was prepared at a starting
concentration of 1 mM with 1/10 serial dilution in assay buffer or in the cell
lysate with a final concentration of 5 mM DTT. Ubiquitination reactions for
p53 using E3 ligases were carried out with E3 kits from Boston Biochem
according to the protocols described therein, and then, where indicated,
reactions were quenched with 50 mM EDTA and further incubated with 1 mM
USP2CD for 30 min at 37
C.
Cell Culture, Plasmid Transfection, Lysate Preparation,
and Immunoprecipitation
U2OS and HEK293 cells were maintained as previously described (Huang
et al., 2006). Transfections were carried out using Fugene (Promega) or
Hiperfect (QIAGEN), for plasmids or siRNA oligos, respectively, according to
the manufacturer’s protocol. The siRNA used to knock down Rad18 has
been described previously (Huang et al., 2006). Cells were routinely harvested
in PBS, and the pellets were frozen at 80C prior to lysis. Cells were lysed in
either denaturing SDS buffer (100mM Tris [pH 6.8], 2%SDS and 20mM b-Me)
for direct analysis by SDS-PAGE or in nondenaturing buffer (50 mM Tris
[pH 7.6], 150 mM NaCl, 2 mM EDTA, 0.5% NP-40, and protease inhibitor
cocktail [Roche], and benzoase [Novagen]) for immunoprecipitations (IPs)
and ubiquitin-receptor binding assays.
Ubiquitin-Receptor Binding Assays
Cell lysates prepared under nondenaturing conditions (150 mg) were incubated
with 10 ml agarose-conjugated ubiquitin-receptors (RAP80-UIMs or836 Cell Reports 5, 826–838, November 14, 2013 ª2013 The AuthorsS5a/Angiocidin, Boston Biochem) for 1 hr at 4C in binding buffer (50 mM
Tris [pH 8.0], 150mMNaCl, 0.1%NP-40, 5mMDTT, supplemented with a pro-
tease inhibitor cocktail [Roche]) and then washed three times in binding buffer
and analyzed by SDS-PAGE and western blotting.
Plasmids and Recombinant Protein Expression
For the purification of untagged human ubiquitins (linear diubiquitin and
monoubiquitin mutants), ubiquitin (residues 1–76) was cloned as a His6-
SMT3-fusion protein (plasmid is gift from Chris Lima). Briefly, SMT3-Ub
proteins were expressed in E. coli codon-plus cells at 30C for 3 hr by inducing
expression with 1 mM IPTG. His6-SMT3-Ub proteins were purified by Ni
2+-
NTA and size exclusion chromatography on a Superdex-200 26/60 column
in 20 mM Tris (pH 8.0), 350 mMNaCl, and 1 mM b-Me. The purified fusion pro-
tein was cleaved overnight at 4C with Ulp1 at a molar ratio of 1:1,000; next,
untagged ubiquitin was separated from His6-SMT3 by a final ion-exchange
step on a MonoQ 10/10 column. Untagged ubiquitin proteins produced this
way have additional SerGly residues at their N termini owing to the cloning
strategy using BamHI-XhoI. For mammalian expression, ubiquitin (residues
2–76) was subcloned into pcDNA3 with an N-terminal HA tag using the restric-
tion sites HindIII and XhoI and has been used as a template to obtain the
indicated point mutants by site-directed mutagenesis. The catalytic domain
of human USP2a (residues 259–605) was cloned with a C-terminal His-tag in
pET21a and expressed as previously. Briefly, USP2CD was expressed in
E. coli codon-plus cells at 30C for 5 hr by inducing with 1 mM IPTG. USP2CD-
His was then purified by Ni2+-NTA and size-exclusion chromatography on a
Superdex-75 26/60 column in 20 mM HEPES (pH 7.0), 350 mM NaCl,
and 1 mM b-Me, followed by a final ion-exchange step on a MonoS 10/10
column. Recombinant S. pombe E1 (Uba1) was a gift from Shaun K. Olsen;
other enzymes have been purchased from Boston Biochem. USP1/UAF1
was purchased from Ubiquigent. All constructs have been verified
by sequencing and all recombinant proteins have been aliquoted and stored
at 80C until use.
Antibodies
The following antibodies were used in this study: antiubiquitin (P4D1, sc-8017,
Santa Cruz Biotechnology), anti-His (mouse-monoclonal, GenScript), anti-HA
(Mono HA.11, MMS-101R, Covance), anti-PCNA (PC10, sc-56, Santa Cruz),
anti-MCM6 (A300-194A-2, Bethyl Laboratories), anti-Rad18 (A301-340A,
Bethyl Labs), anti-MCM4 (A300-193A, Bethyl Labs), anti-myc (c-3956, Sigma),
anti-GFP (B-2, sc-9996, Santa Cruz), and anti-p53 (Boston Biochem).
Immunofluorescence Microscopy
Cells were grown and processed in 8-well Lab-Teks II ChamberSlide System
slides from Nunc. For the bleomycin recovery experiment, cells were treated
with 5 mg/ml bleomycin sulfate (Calbiochem) for 1 hr at 37C and then, where
indicated, recovered in full media for 24 hr and fixed using methanol fixation
and stained with HA and 53BP1 antibodies. GFP-Pol-eta nuclear foci
formation was detected after methanol fixation, and cells were stained with
anti-GFP for 2 hr at room temperature. The secondary antibodies used were
Alexa-conjugated goat anti-mouse and anti-rabbit. Slides were mounted in
Vectashield with DAPI (Vector Laboratories). Images were deconvolved using
Softworx software (Applied Precision). The images were opened and then
sized and placed into figures using ImageJ. At least 50 GFP/HA-positive nuclei
were counted per chamber and were quantified for containing more than ten
nuclear GFP-eta foci. Error bars represent SD of the mean, n = 3.
MEFs
MEFs from E13.5 embryos obtained from crosses between Rosa26 CRE-ER
mice (Jackson ImmunoResearch Laboratories) and mice carrying a condi-
tional TRF2 allele (Celli and de Lange, 2005) were immortalized at passage 2
with pBabeSV40LT. Ubiquitin-HA constructs were introduced by retroviral
infection using the following constructs: pLPC-HA-Ub and pLPC-HA-
Ub-L73P. IR treatments, metaphase spreads, and FISH/IF costaining were
performed as described previously (Okamoto et al., 2013); 53BP1 was
detected using a rabbit polyclonal antibody (Novus Biologicals, NB
100-304). Experiments were repeated in triplicates, and 53BP1 foci were
scored in at least 200 cells for each experiment. Data reported are averages of
three independent experiments error bars represent SD.
Stable Cell Lines
HeLa cells expressing doxycycline-inducible FLAG-Ub-WT and FLA-
G-Ub-L73P were generated using Flippase (Flp) recombination target
(FRT)/Flp-mediated recombination technology in HeLa-T-rex Flp-in cells,
as described previously (Tighe et al., 2008). Cells were induced with 1 mg/ml
doxycycline for the indicated times to induce transgene expression. For a
medium scale mass spectrometry study, Flp-in UbL73P cells (36 3 15 cm
dishes) were grown to 60% confluency and induced with 1 mg/ml doxycy-
cline for 48 hr. Cells were briefly pelleted and frozen at 80C until further
processing.
FLAG immune Precipitation of Flp-in UbL73P Cells
Cell pellets were lysed in mRIPA buffer (20mM Tris [pH 7.5], 1% NP-40, 0.5%
CHAPS, 0.1% SDS, and 150 mM NaCl) supplemented with protease inhibitor
cocktail (Roche) and 1 U/ml benzoase (Novagen), for 1 hr on ice. Lysates were
cleared by centrifugation and the supernatant was incubated 100 mg M2-
conjugated (anti-FLAG) magnetic DynaBeads (Sigma-Aldrich) for 1 hr at 4C.
The beads were extensively washed in mRIPA buffer, then in 100 mM
ammonium bicarbonate (pH 8) and immediately processed for mass-
spectrometry-grade trypsin digest.
Mass Spectrometry
Immunoprecipitated proteins were reduced with the addition of 0.02 M dithio-
threitol (pH 8) for 1 hr at 57C and subsequently alkylated using 0.05 M
iodoacetic acid (pH 8) for 45min in the dark at room temperature. The samples
were proteolytically digested with trypsin (Promega) at a 1:20 enzyme to
substrate ratio overnight with gentle shaking at room temperature. The
resulting peptide mixture was removed from the beads and adjusted to pH 3
with trifluoroacetic acid prior to desalting using a C18 Stage tip procedure,
as previously described (Cotto-Rios et al., 2012; Rappsilber et al., 2007; Wu
et al., 2012). The desalted peptide mixture was concentrated in a SpeedVac
concentrator to remove organic solvents. A tenth of the peptide mixture was
loaded onto a Acclaim PepMap 100 precolumn (75 mm 3 2 cm, C18, 3 mm,
100 A˚, Thermo Scientific) that was connected to an EASY-Spray, PepMap
RSLC column (75 mm 3 25 cm, C18, 2 mm, 100 A˚ Thermo Scientific) with a
5 mm emitter using the autosampler of an EASY-nLC 1000 (Thermo Scientific).
Peptides were gradient eluted from the column directly into a Q Exactive mass
spectrometer (Thermo Scientific) using a 120 min gradient from 2% solvent B
to 40% solvent B. Solvent A was 2% acetonitrile in 0.5% acetic acid and
solvent B was 90% acetonitrile in 0.5% acetic acid. High-resolution MS1
spectra were acquired with a resolution of 70,000, an AGC target of 1e6,
with a maximum ion time of 120 ms, and scan range of 400 to 1,500 m/z.
Following each MS1, 20 data-dependent high-resolution HCD MS2 spectra
were acquired. All MS2 spectra were collected using the following instrument
parameters: resolution of 17,500, AGC target of 5e4, maximum ion time of
250 ms, one microscan, 2 m/z isolation window, fixed first mass of 150 m/z,
30 s exclusion list, and NCE of 27.
Database Search
All MS2 spectra were searched against a uniprot human database using
Sequest via Proteome Discoverer (Thermo Scientific). For the search
trypsin was indicated as the enzyme, precursor mass tolerance was set
to ±10 ppm, and fragment ion mass tolerance was set to ±0.02 Da. Carboxy-
methylation of Cys was searched as a static modification. The following
variable modifications were also searched: diglycylation of Lys, deamidation
of Gln and Asp, and oxidation of Met. Peptides identified as having a diglycy-
lated lysine were manually validated.SUPPLEMENTAL INFORMATION
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